Comparison of Sequential to Initial Combination Therapy in PAH

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.
Epistemonikos ID: b1a1a25c02e75770f408e6225ea1b2213e067972
First added on: May 14, 2025